Vying for Market Share, Companies Heavily Promote . But now, a furious battle is underway among the makers of three newer competitors for the prescription pads of doctors across the country. Beginning in 2. 01. Use this tool to search for a company, drug or device — and compare it to another. Explore the app (Lena Groeger, Ryann Grochowski Jones, Charles Ornstein and Mike Tigas, Pro. Publica)The manufacturers of these drugs — Pradaxa, Xarelto and Eliquis — have been wooing physicians in part by paying for meals, promotional speeches, consulting gigs and educational gifts. In the last five months of 2. Pro. Publica's analysis of federal data released last fall. The information, from a database known as Open Payments, gives the first comprehensive look at how much money drug and device companies have spent working with doctors. What it shows is that the drugs most aggressively promoted to doctors typically aren't cures or even big medical breakthroughs. Some are top sellers, but most are not. Instead, they are newer drugs that manufacturers hope will gain a foothold, sometimes after failing to meet Wall Street's early expectations. Joseph Ross, an associate professor of medicine and public health at Yale University School of Medicine. Companies typically try to differentiate the new drugs by claiming they are easier to use; carry fewer side effects; work faster than competitors; or have medical advantages. The makers of Pradaxa, Xarelto and Eliquis, for example, say their drugs are at least as effective as Coumadin for certain conditions but do not require routine blood tests or limitations on what patients can eat.
Murphy said. According to Pro. Publica's analysis, Victoza, a diabetes medication made by Novo Nordisk, was the drug associated with the most payments to doctors, by dollar amount. The company spent more than $9 million on physician interactions related to Victoza in the last five months of 2. Todd Hobbs, chief medical officer of Novo Nordisk in North America, said the company's spending reflected Victoza's newness and the need to address such safety concerns. In a statement, the companies said their spending helps ensure physicians understand the appropriate use of Eliquis. Because the drug is prescribed by physicians in different specialties, the statement said, . In an email, Astra. Zeneca said it had identified Brilinta as one of its . But this covers only 1. It has no information from medical device makers. The list of most promoted drugs featured many recent arrivals: 1. Food and Drug Administration since 2. Some treat similar conditions, including diabetes, schizophrenia and chronic obstructive pulmonary disease, so the competition among them is fierce. If a drug is either the first to treat a disease or is much better than existing drugs, said Dr. NEW Anti-Obesity Medicines. Now that everyone acknowledges obesity is a disease, anti-obesity medicines must be viewed from a new perspective. ProPublica is investigating the financial ties between the medical community and the drug and device industry. In October 2010, ProPublica compiled the list of. Sidney Wolfe, the founder and now senior adviser to Public Citizen's Health Research Group, . The manufacturers of several others, including Copaxone, Latuda, Xarelto, Daliresp and Humira, have been faulted by the F. D. A. It's often prescribed for off- label, or unapproved, uses; in November, The New York Times reported that some of the doctors paid the most to promote the drug had disciplinary or legal troubles. In a statement to The Times, Insys Therapeutics, the drug's maker, said its marketing of Subsys was appropriate. The medical device associated with the most payments to doctors was Intuitive Surgical's da Vinci surgical robot system, which the company has marketed as an effective, less invasive option for an array of procedures. Critics have complained that the device is needlessly expensive and overused, and say it has been linked to patient complications and deaths. Intuitive spent nearly $1. The spokeswoman Paige Bischoff said in an email that about half of the company's outlays for education and training were . Robert Takla, an emergency room physician in the Detroit area, earned about $7. Brilinta, according to Open Payments. He said he enjoys speaking on behalf of companies and thinks he offers a different perspective than cardiologists and internists — the usual prescribers of the drugs — because he treats complications of blood clots in the emergency room. Dr. Takla said he reviews clinical studies before deciding to speak for a drug and turns companies down when he isn't impressed. He said he no longer spoke on behalf of Pradaxa because of what he characterized as public backlash against it, driven by a spate of lawsuits against its manufacturer, Boehringer- Ingelheim.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
November 2017
Categories |